Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy

被引:17
作者
Jessen, Christian [1 ]
Agerbaek, Mads [1 ]
Von Der Maase, Hans [1 ]
机构
[1] Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus C, Denmark
关键词
ADVANCED BLADDER-CANCER; UROTHELIAL CANCER; GEMCITABINE; METHOTREXATE; COMBINATION; TUMORS; TRIAL; VINBLASTINE; DOXORUBICIN; PACLITAXEL;
D O I
10.1080/02841860802325932
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. The study was undertaken to identify pre-treatment clinical and histopathological factors of importance for response and survival after cisplatin-based combination chemotherapy, in patients with locally advanced or metastatic transitional cell carcinoma of the urothelium. Patients and methods. Clinical, laboratory and histopathological data from 178 consecutive patients, representing all patients treated between 1991 and 2001 in a single institution, were collected. Correlations between these data and response and survival after chemotherapy were analysed using univariate and multivariate analyses. Results. Absence of visceral metastasis was the only parameter with independent correlation to the response to chemotherapy. Two of the analysed parameters were independently associated with increased survival: good performance status (PS1) and absence of visceral metastases. Stratification of the patient material according to number of these risk-factors present showed strong association with survival. Conclusion. It was possible to predict survival from pre-treatment clinical parameters and consequently it is possible to select groups with a high and low probability of obtaining long term survival following cisplatin-containing chemotherapy.
引用
收藏
页码:411 / 417
页数:7
相关论文
共 24 条
[1]  
Andersen LJ, 1998, ACTA ONCOL, V37, P110
[2]  
[Anonymous], 1979, HDB REP RES CANC TRE
[3]   Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy [J].
Bajorin, DF ;
Dodd, PM ;
Mazumdar, M ;
Fazzari, M ;
McCaffrey, JA ;
Scher, HI ;
Herr, H ;
Higgins, G ;
Boyle, MG .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3173-3181
[4]   Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine [J].
Bellmunt, J ;
Albanell, J ;
Paz-Ares, L ;
Climent, MA ;
González-Larriba, JL ;
Carles, J ;
de la Cruz, JJ ;
Guillem, V ;
Díaz-Rubio, E ;
Cortés-Funes, H ;
Baselga, J .
CANCER, 2002, 95 (04) :751-757
[5]   Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium [J].
Bellmunt, J ;
Guillem, V ;
Paz-Ares, L ;
González-Larriba, JL ;
Carles, J ;
Batiste-Alentorn, E ;
Sáenz, A ;
López-Brea, M ;
Font, A ;
Nogué, M ;
Bastús, R ;
Climent, MA ;
de la Cruz, JJ ;
Albanell, J ;
Banús, JM ;
Gallardo, E ;
Diaz-Rubio, E ;
Cortés-Funes, H ;
Baselga, J .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (18) :3247-3255
[6]  
Bergkvist A, 1965, Acta Chir Scand, V130, P371
[7]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[8]   A RANDOMIZED COMPARISON OF CISPLATIN ALONE OR IN COMBINATION WITH METHOTREXATE, VINBLASTINE, AND DOXORUBICIN IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA - A COOPERATIVE GROUP-STUDY [J].
LOEHRER, PJ ;
EINHORN, LH ;
ELSON, PJ ;
CRAWFORD, ED ;
KUEBLER, P ;
TANNOCK, I ;
RAGHAVAN, D ;
STUARTHARRIS, R ;
SAROSDY, MF ;
LOWE, BA ;
BLUMENSTEIN, B ;
TRUMP, D .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (07) :1066-1073
[9]  
LOHRER PJ, 1992, J CLIN ONCOL, V10, P1066
[10]  
MEAD GM, 1998, BRIT J CANCER, V78, P1967